Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Local Anesthetics: Differential Sensitivity of Nerve Fibers01:24

Local Anesthetics: Differential Sensitivity of Nerve Fibers

1.7K
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
1.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

782
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
782

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetic Resonance Imaging Segmentation of Soft Tissue in the Diagnosis of Chronic Low Back Pain: A Scoping Review.

Diagnostics (Basel, Switzerland)·2026
Same author

Spinal mechanisms and feasibility of Dry Needling versus Botulinum Toxin Type A in post-stroke lower limb spasticity: A proof-of-concept randomized clinical trial protocol (STROKE-POC).

PloS one·2026
Same author

Artificial Intelligence Meets Cancer Rehabilitation: Emerging Evidence for Exercise and Physical Activity Interventions.

Cancer control : journal of the Moffitt Cancer Center·2026
Same author

Immediate Postoperative Ultrasound Assessment of Quadriceps Muscle and Femoral Nerve Morphology After Total Knee Arthroplasty: A Methodological Feasibility Study.

Physiotherapy research international : the journal for researchers and clinicians in physical therapy·2026
Same author

Selective Motor Entropy Modulation and Targeted Augmentation for the Identification of Parkinsonian Gait Patterns Using Multimodal Gait Analysis.

Life (Basel, Switzerland)·2026
Same author

Can Artificial Intelligence Align with Evidence? Performance of ChatGPT-4o in Knee Osteoarthritis Surgical Guidelines.

The journal of knee surgery·2026

Related Experiment Video

Updated: Apr 12, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.3K

Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy: A Case Report.

Sara Mogedano-Cruz1, Carlos Romero-Morales1, Mónica de la Cueva-Reguera1

  • 1Department of Physiotherapy, Faculty of Medicine, Health and Sports, European University of Madrid, Villaviciosa de Odón, 28670 Madrid, Spain.

Reports (MDPI)
|August 22, 2025
PubMed
Summary

Percutaneous electrical nerve stimulation (PENS) effectively managed chemotherapy-induced peripheral neuropathy (CIPN) in a colorectal cancer patient. This non-invasive approach improved nerve symptoms without interrupting oxaliplatin treatment, showing promise for cancer patients.

Keywords:
chemotherapy-induced peripheral neuropathycolon cancerneuropathic painoxaliplatinpercutaneous electrical nerve stimulation

More Related Videos

Assessment of Neuromuscular Function Using Percutaneous Electrical Nerve Stimulation
07:53

Assessment of Neuromuscular Function Using Percutaneous Electrical Nerve Stimulation

Published on: September 13, 2015

22.1K
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.6K

Related Experiment Videos

Last Updated: Apr 12, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.3K
Assessment of Neuromuscular Function Using Percutaneous Electrical Nerve Stimulation
07:53

Assessment of Neuromuscular Function Using Percutaneous Electrical Nerve Stimulation

Published on: September 13, 2015

22.1K
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.6K

Area of Science:

  • Oncology
  • Neurology
  • Pain Management

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of oxaliplatin, impacting patient quality of life and treatment adherence.
  • Current pharmacological treatments for CIPN have limited efficacy.
  • Percutaneous electrical nerve stimulation (PENS) is explored as a non-invasive option for CIPN symptom management.

Observation:

  • A 75-year-old female with colorectal adenocarcinoma developed CIPN after oxaliplatin treatment.
  • The patient received a 12-week course of PENS targeting the median nerve, with weekly sessions.
  • Chemotherapy was continued without interruption, and no adverse effects were reported during PENS treatment.

Findings:

  • The patient demonstrated progressive improvement in neurosensory symptoms, validated by the EORTC QLQ-CIPN20 questionnaire.
  • Quantitative sensory testing indicated normalization of thermal and vibratory sensitivity.
  • Mechanical detection thresholds improved, and the full cumulative oxaliplatin dose was administered.

Implications:

  • PENS shows promise as a safe and effective option for managing CIPN.
  • This approach may allow for symptom control, enabling the continuation of essential oncological treatment.
  • Further controlled clinical trials are warranted to establish PENS efficacy and standardize protocols for CIPN management.